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One of the defining pathological features of Alzheimer disease (AD) is the intraneuronal
accumulation of tau.The tau that forms these accumulations is altered both posttranslation-
ally and conformationally, and there is now significant evidence that soluble forms of these
modified tau species are the toxic entities rather than the insoluble neurofibrillary tangles.
However there is still noteworthy debate concerning which specific pathological forms of
tau are the contributors to neuronal dysfunction and death in AD. Given that increases in
aberrant forms of tau play a role in the neurodegeneration process in AD, there is growing
interest in understanding the degradative pathways that remove tau from the cell, and the
selectivity of these different pathways for various forms of tau. Indeed, one can speculate
that deficits in a pathway that selectively removes certain pathological forms of tau could
play a pivotal role in AD. In this review we will discuss the different proteolytic and degrada-
tive machineries that may be involved in removing tau from the cell. How deficits in these
different degradative pathways may contribute to abnormal accumulation of tau in AD will
also be considered. In addition, the issue of the selective targeting of specific tau species
to a given degradative pathway for clearance from the cell will be addressed.
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INTRODUCTION
Insoluble, fibrillar intraneuronal accumulations of pathological
forms of the tau protein called neurofibrillary tangles (NFTs) are
important and defining hallmarks of the Alzheimer disease (AD)
brain. Indeed, the progression of AD can be neuropathologically
staged based on the location and extent of tau pathology (1).
The predominant post-translational modification of tau in the
NFTs is phosphorylation; however numerous modifications have
been noted including truncation, acetylation, nitration, and sev-
eral others (2–4). Historically the NFTs were considered to be
the toxic entities, however over the past decade a new concep-
tual framework has developed in which pathologically modified
monomeric and/or soluble oligomeric forms of tau are consid-
ered to be the harmful species (5, 6). Nevertheless, determining
exactly which forms of tau compromise neuronal function is still
an area of significant investigation. Even though the modifica-
tions of tau that are the primary contributors to toxicity have
not been conclusively determined, it is clear that tau plays an
essential role in the pathogenesis of AD. Given that in animal
models of AD reducing tau levels attenuates neuronal dysfunc-
tion (7, 8), and in humans the extent of tau pathology correlates
with cognitive decline (9), there is a growing interest in defining
the degradative pathways that remove tau from the cell. Also of
importance is understanding the role of non-degradative cleavage
in influencing the eventual clearance of tau. Numerous proteases
have been shown to proteolyze tau including aminopeptidases
(10–12), thrombin (13–15), human high temperature require-
ment serine protease A1 (HTRA1) (16), calpain (17–20), and
caspases (21–24). Overall, however, most of these enzymes do not
appear to be principally responsible for tau clearance. Instead,
they are able to generate modified tau species which may then
contribute to developing tau pathology, enhanced tau clearance,
or both. The bulk of clearance of both physiological and patho-
logical forms of tau is instead mediated by the proteasomal and
autophagic degradative systems (25). The contribution of each
of these pathways in the turnover of tau, and which forms of
tau – including various proteolytic forms – are degraded by
each pathway, is an area of significant interest. Our understand-
ing of this issue to date will be reviewed below, and the role
of tau proteolysis on subsequent degradation will be discussed.
Delineating how these pathways may be compromised in AD
and how this contributes to tau pathology is of great impor-
tance and could have significance for informing new therapeutic
approaches.
TAU PROTEOLYSIS
Tau is a cytosolic, dynamically regulated protein. In differenti-
ated PC12 cells, a pulse-chase experiment showed that ∼90%
of the tau was degraded in 18 h (26). Normal, monomeric tau
is likely a proteasomal substrate. However, there is evidence
that tau is also a substrate for a wide range of proteases as
indicated above. This is significant as tau proteolysis could be
beneficial in disease by helping to enhance removal of abnor-
mal tau from the cell. Alternately, it could be detrimental by
generating toxic fragments. Below we will discuss the differ-
ent proteases that have been shown to act on tau, at least
in vitro, and the possible involvement of these proteolytic events
in AD.
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AMINOPEPTIDASES
Aminopeptidases are a group of enzymes that cleave from the
N-terminal end of a protein. The family includes alanyl, arginyl,
and glutamyl peptidases. Puromycin sensitive aminopeptidase
(PSA) is an alanyl peptidase that is responsible for ∼90% of the
aminopeptidase activity in the brain (10). PSA was identified as
a potential player in tau pathology through a microarray analy-
sis of gene expression in disease-vulnerable vs. disease-resistant
brain regions in JNPL3 mice that overexpress a mutant form
of tau (P301L) found in the disease frontotemporal dementia
and parkinsonism linked to chromosome 17 (FTDP-17). These
mice develop neurodegeneration in the cortex while the cerebel-
lum is relatively spared [although in the original description of
these animals pathology was found in the deep cerebellar nuclei
(27)]. Interestingly, PSA was found to be elevated in the cere-
bellum of these TAUP301L mice (10). The levels of PSA are also
higher in human cerebellum compared to cortex in both controls
and FTD cases. A slight elevation in PSA was also observed in
FTD cortices compared to controls. In addition, a non-functional
PSA mutant exacerbated tau pathology in a Drosophila model of
tauopathy, while overexpressing PSA ameliorated the tau pheno-
type and diminished tau levels (10). Overexpressing PSA had a
similar effect in the TAUP301L mice, reducing the pathologic phe-
notype (delaying paralysis, increasing motor neuron density in the
spinal cord, decreasing gliosis) and decreasing tau levels (12). PSA
was able to cleave recombinant tau in vitro, as well as tau from con-
trol human brain (11). However, the data presented in this study
suggest that PSA is cleaving tau from both the C- and N-terminal
ends, which is not expected from an aminopeptidase. Addition-
ally, other studies failed to demonstrate tau cleavage by PSA (28,
29). One explanation for these discrepancies may be the limita-
tions of in vitro assays and experimental techniques. For example,
the FTDP-17 mutant tau used in many studies, while relevant for
human tauopathy, is not found in AD. Additionally, this form of
tau may be processed differently than tau without this mutation.
For example, it has been shown that the isomerase Pin1, which
has been implicated in AD (30), had opposite effects on P301L
and wild-type tau degradation (31). An alternative explanation
for the effects of PSA may be that PSA is indirectly regulating tau
degradation. PSA has been shown to be involved in the induction
of autophagy and specifically the formation of autophagosomes,
in a model of overexpressed mutant huntingtin (32). Thus, the
in vivo effects of PSA on promoting tau clearance may relate to its
ability to modulate the key clearance pathway for abnormal and
aggregated proteins (to be described in more detail below).
THROMBIN
Thrombin is a serine protease that is a well characterized com-
ponent of the coagulation cascade. It is typically produced and
secreted by endothelial cells, including those in the brain in
response to hemodynamic injury. Thrombin may be inappropri-
ately expressed in AD brain. A recent study showed that thrombin
is elevated in microvessels isolated from AD brain compared to
microvessels from control brain (33). Additionally, thrombin was
present in the CSF of AD patients but not in that of controls (33).
This is important, as thrombin can act as a neurotoxin by acti-
vating intracellular signaling cascades causing neurite retraction
and stimulating apoptosis (34–36). Thrombin may also be influ-
encing tau pathology, as treatment of immortalized hippocampal
neuronal cells (HT22 cells) with thrombin resulted in the forma-
tion of thioflavin-S positive tau aggregates within 24 h, followed
by an increase in cell death at 72 h (37). It is unclear how this
exogenously applied thrombin may be altering tau within the cells.
There are also data to suggest that thrombin may act intracellularly
to mediate tau pathology. Thrombin is expressed within neurons
and astrocytes in both normal and AD brain (38). In AD brain
the staining pattern for thrombin and prothrombin was charac-
teristic of the pattern of NFTs, although these structures were not
colabeled with antibodies for tau (38). Evidence supporting a role
for thrombin in tau proteolysis came initially from an in vitro
study showing that thrombin degraded recombinant full-length
tau from the N-terminus yielding a 25-kDa fragment, while pre-
serving the microtubule binding repeat domain (13). A later study,
however, showed that in N2a neuroblastoma cells expressing a con-
struct of only the tau repeat domain, thrombin cleavage could still
occur, indicating additional cleavage sites (15). Similar results were
observed in an in vitro assay (15).
The products of thrombin proteolysis are potentially patho-
genic. Thrombin cleavage of the repeat domain construct yielded
fragments that rapidly aggregated, which closely correlated with
toxicity in cell culture (15). These fragments can also induce the
aggregation of full-length tau (39). A final point of interest relates
to potential upstream modifications of tau. Endogenous tau is
phosphorylated, and in AD, tau phosphorylation becomes dysreg-
ulated. This may interfere with subsequent processes including
cleavage and degradation. For example, tau that is in the cis-
conformation at T231 appears resistant to degradation, as cis-tau
is found in dystrophic neurites while trans-tau is not. Additionally
cis-tau partitions to the insoluble fraction (30). Phosphorylation at
T231 prevents the isomerase Pin1 from converting cis-tau to trans-
tau (30). Interestingly, phosphorylation of tau also appears to dis-
rupt some thrombin cleavage sites, changing the pattern of cleav-
age without impeding the thrombin-mediated proteolysis (14, 28).
It has yet to be determined whether there is a difference in toxi-
city potential between fragments generated from phosphorylated
vs. unphosphorylated tau. Nonetheless, thrombin is a potential
candidate for contributing to tau proteolysis and pathology.
HUMAN HIGH TEMPERATURE REQUIREMENT SERINE PROTEASE A1
Another serine protease recently implicated in tau processing is
HTRA1. This is a ubiquitously expressed, ATP-independent intra-
cellular protease. Expression is detectable in many tissues, includ-
ing the nervous system, although expression is low (40). Nonethe-
less, this enzyme was initially implicated in AD because it may
play a role in amyloid processing (41). Tubulin was later identified
as a substrate for HTRA1, suggesting HTRA1 may be involved in
mediating microtubule function (42, 43). A more recent study
showed that HTRA1 can cleave recombinant tau in vitro into
multiple fragments of varying sizes, and furthermore can degrade
insoluble and fibrillarized tau (16). This ability to degrade aggre-
gates is particularly intriguing, especially in light of the fact that
HTRA1 has potential chaperone activity due to its C-terminal PDZ
domains and has a preference for misfolded substrates (44). While
more work needs to be done on the role this enzyme plays in
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tau proteolysis, these findings further indicate the complexity and
likely involvement of multiple players in this process.
CALPAINS
Calpains are calcium-activated cytosolic cysteine proteases. Two
isoforms differentiated and named by their sensitivities to calcium
(i.e.,µ-calpain and m-calpain, also called calpain-1 and calpain-2)
are abundant in the central nervous system, and respond to micro-
molar and millimolar concentrations of calcium, respectively (45).
Calpain has been implicated in a number of neurodegenerative
diseases [for a review, see (46)]. The active form of calpain-2 is
found in 50–75% of NFTs in tauopathies including AD, but not
in protein aggregates found in other diseases (47). This is con-
sistent with another study that found equivalent calpain levels
between control and AD cases, but the activity level of the enzyme
isolated from AD brain tissue was increased (48). Excitotoxicity
leading to elevated intracellular calcium is a common feature of
neurodegenerative diseases, and is implicated in AD (49, 50). This
process may lead to enhanced activation of calpains (51). This in
turn could influence a number of pathologic processes, includ-
ing tau proteolysis. Indeed, tau has a number of putative calpain
cleavage sites, and incubation of recombinant tau with calpain gen-
erates specific fragments, including one that is ∼35 kDa and one
that is∼17 kDa (19, 20). Increasing intracellular calcium levels in
PC12 cells leads to calpain-induced cleavage of tau (18). This may
reflect a potential effect of excitotoxicity in AD. Inducing apoptosis
in cerebellar granule cells yields calpain-mediated tau fragments,
including a dominant ∼17 kDa fragment (17). Also, treating pri-
mary hippocampal neurons with pre-aggregated amyloid β (Aβ)
led to the generation of tau fragments of ∼35,∼24, and∼17 kDa,
which was blocked by addition of a calpain inhibitor (52, 53). Tau
fragments of the same size were also found in AD brain tissue (19).
The pathological role of this calpain-cleaved tau is unclear.
While some studies demonstrate toxicity resulting from calpain
proteolysis of tau, other studies do not support this conclusion.
On the one hand, expressing a 17-kDa fragment of tau based
on calpain cleavage site mapping in hippocampal neurons led to
neurite retraction and the appearance of varicosities after 48 h
(52). Additionally, suppressing calpain activity in a fly model
of tauopathy prevented neurodegeneration, as did expressing a
calpain-resistant form of tau (54). In contrast, another study used
mass spectroscopy and sequencing to identify the “17 kDa” tau
cleavage product and found it did not correspond to the recom-
binant fragment utilized in the above studies (19). Expression of
a recombinant form of the mass spectroscopy-identified fragment
in hippocampal neurons was not toxic (19). Further studies are
needed to clarify the contribution of calpain-mediated proteolysis
of tau to AD pathology.
CASPASES
There is significant evidence that tau is a caspase substrate and
that caspase-mediated tau cleavage may play a role in AD pathol-
ogy. Early in vitro studies demonstrated that tau is cleaved in the
C-terminus by several caspases including caspase-3 and caspase-
6 (21–23). Caspase-6 was also shown to cleave the N-terminus
of tau in vitro (24). Caspase-3, which is a key effector in the
apoptotic cascade, cleaves tau predominantly at the C-terminal
D421 site generating a fragment often referred to as tauC3 (22, 23).
There may be reciprocity with the apoptosis pathway as activating
caspase-3 by inducing apoptosis in cortical neuronal culture led to
tau cleavage (22), and selectively expressing tauC3 led to apoptosis
in NT2 and COS cells (21). This might represent a feed-forward
loop of neurotoxicity. Furthermore, expressing a cleavage resistant
form of tau (D421E) protects cells from apoptotic cell death (22).
Another potential mechanism of inducing caspase-3 cleavage of
tau is the presence of Aβ peptides. TauC3 is formed in primary
cortical neurons after treatment with Aβ (23).
Caspase cleavage of tau may play a role in stimulating the tau
aggregation seen in AD. Indeed, in vitro polymerization assays
demonstrate that caspase-cleaved tau has a greater propensity to
aggregate compared to full-length tau (23, 55). Intriguingly, cas-
pase activation was shown to immediately and consistently precede
the formation of tangles (56). This group used in vivo multiphoton
imaging in Tg4510 TAUP301L mice to simultaneously image acti-
vated caspases and Thioflavin-S positive tau tangles. There was
a strong correlation between active caspases and the presence of
tangles within viable neurons. In the few cells found that were
caspase-positive and tangle-negative, 88% had tangles within 24 h
(56). This seems to further support a role for caspase cleavage in
the evolution of tau pathology.
In order for caspase to cleave tau in the AD brain, it needs to be
present in its active form. The active forms of both caspase-3 and
caspase-6 are elevated in AD-specific brain regions (temporal and
frontal lobes) compared to unaffected regions (cerebellum) and
control brains (57, 58). Furthermore, active caspase co-localizes to
NFTs (58), and caspase-cleaved tau is found in AD-affected brain
regions, particularly in neurons displaying tangle pathology (59,
60). This includes tau cleaved by caspase-6 in the C-terminus (58–
60) as well as in the N-terminus (24). TauC3 is present in AD
brain – in neurons and co-localized with NFTs – and inversely
correlates with cognitive function (55, 60, 61).
The activation of caspases and the subsequent cleavage of tau
is likely to occur independent of apoptotic cell death (56). The
processes that may result in the activation of caspases in an apop-
tosis independent manner have not been clearly delineated; how-
ever several possibilities have been suggested. First, inflammation,
which is a common feature of AD, may contribute to tau pathol-
ogy by activating caspases. Treating cells with the prostaglandin
cyclopentenone byproduct PGJ2 increased caspase activity and
increased cleaved tau (62). Thrombin signaling can also activate
caspases (36). Proteasomal impairment appears to be upstream of
caspase activation, as inhibiting the proteasome with epoxomicin
(EPX) led to activation of caspase-3 in primary neurons (63) and
in a neuroblastoma cell line expressing wild-type tau (64). In
both studies caspase activation correlated with the appearance and
increase over time of caspase-cleaved tau species, which appeared
to subsequently form aggregates in the neurons (63). While the
mechanism is unclear, a possibility is that accumulating proteins
might be a factor in initiating caspase activation.
PROTEOLYSIS vs. DEGRADATION
As discussed above, a number of enzymes have been shown to
act on tau, under potentially pathological, as well as physiologi-
cal conditions. Many of these enzymes cleave tau at discrete sites,
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generating specific fragments. Some of these fragments, such as
those generated by thrombin, calpain, and caspase, are potentially
toxic to the cell if they accumulate due to inefficient clearance
mechanisms. Figure 1 illustrates the potential contribution of
these different proteases to the processing of tau. These proteolyti-
cally generated tau fragments can show an increased propensity for
self-association, prior to the formation of overt aggregates. Thus,
in the context of enhanced proteolysis (for example by caspases)
there may be increased low-order oligomers formed by cleaved tau
species. These oligomers may be unable to be cleared as effectively
by the cell and contribute to neuronal dysfunction. Therefore coor-
dination between proteolytic processing of tau and clearance by
degradative pathways is essential for maintaining the appropriate
levels of tau in a functional state. Below we will discuss the main
degradative pathways of the cell-the proteasome and autophagy-
which likely clear full-length tau as well as proteolytically generated
tau fragments.
THE PROTEASOME
The proteasome is a multimeric barrel-shaped structure that is
a key complex for clearing soluble cytosolic proteins. The 26S
proteasome has a regulatory cap (19S, or alternatively the 11S reg-
ulatory particle) on either end of its catalytic core (20S), which
contains the proteolytic activities and degrades substrates tagged
with poly-ubiquitin chains as the targeting sequence. The regula-
tory cap in conjunction with chaperone proteins unfolds the pro-
tein substrate and removes the ubiquitin tag in an ATP-dependent
process prior to feeding the protein into the catalytic core, where
it is systematically degraded by the enzymatic properties of the
proteasome. The 20S proteasome, which is the catalytic core with-
out its regulatory caps, is also able to degrade natively unfolded
substrates directly through an ATP- and ubiquitin-independent
process. As shown in Figure 2, tau is an ideal proteasomal sub-
strate for either form of the proteasome because it is a relatively
small, unfolded, short-lived cytosolic protein (64–67).
The accumulation of proteins in AD patients’ brains generated
interest in the role of proteasomal function. There is evidence sug-
gesting that proteasomal activity, but not protein level, is decreased
in AD-sensitive brain regions specifically compared to unaffected
regions (68, 69). Additionally, tau appears to be physically asso-
ciated with the proteasome in brain tissue from AD cases. When
tau was immunoprecipitated it pulled down both the 26S and
20S proteasomes, while immunoprecipitating for the 20S catalytic
core pulled down tau (69). This suggests tau is being targeted to
the proteasome, but may also indicate impaired ability to complete
degradation; hence it is remaining associated with the proteasome.
Further, there was an inverse correlation between proteasomal
activity and high molecular weight forms of tau (69). This may
suggest that abnormal proteins themselves may interfere with pro-
teasomal degradative processes. Indeed, in vitro aggregated paired
helical filament tau could inhibit proteasome activity (69).
EVIDENCE THAT TAU IS DEGRADED BY THE PROTEASOME
A number of studies have used various in vitro techniques to
analyze proteasomal degradation of tau. These include cell cul-
ture and cell free studies. Not surprisingly, if recombinant tau
is incubated with isolated 20S proteasomal complexes, degrada-
tion occurs (65). In this system proteolysis is bidirectional. Also,
if tau is first ubiquitylated in an in vitro reaction and then incu-
bated with isolated 26S proteasomes supplemented with MgCl2
and ATP, degradation proceeds (66). These data indicate tau can
be a substrate for both forms of the proteasome. Similar data has
been obtained from studies using various cell culture systems as
well as animal tissue and primary cultures with a variety of protea-
somal inhibitors. When HEK cells are co-transfected with tau and
ubiquitin, tau accumulates in the insoluble fraction. Its accumu-
lation in the insoluble fraction is enhanced by proteasomal inhi-
bition (using ALLN or MG-132) suggesting that tau is degraded
by the proteasome (66). In SH-SY5Y neuroblastoma cells, treat-
ment with lactacystin, a selective inhibitor of the 20S catalytic
FIGURE 1 | Proteolytic processing of tau. Under pathological and
physiological conditions, tau undergoes cleavage at many distinct
proteolytic sites by a myriad of proteases. The action of these
proteases can lead to both protection and/or exacerbation of pathology.
For example, cleavage of tau by caspase (Casp) 3, caspase-6, calpain
(Calp), and thrombin (Thrm) leads to the production of toxic fragments
of tau that exacerbate pathology. On the other hand, cleavage of tau by
PSA, Htra1, and – in some circumstances – caspase-3, may facilitate its
degradation, which may protect neurons from AD-related neuronal
death.
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FIGURE 2 | Physiological degradation of tau. Tau is degraded by both the
proteasome and autophagy systems. Targeting of tau to either system may be
determined by the extent and nature of post-translational modifications, the
folding state, the level of aggregation, and its interaction with chaperone
proteins or ubiquitin ligases. Monomeric tau is natively unfolded making it a
likely target for the 20S proteasome. Monomeric tau also interacts with the
E3 ligase, CHIP, which can lead to its ubiquitylation and degradation via the
26S proteasome or autophagy. Certain cleavage products and phosphorylated
forms of tau, as well as, monoubiquitylated tau and tau aggregates are
selectively degraded by autophagy.
core, maintained levels of transfected wild-type full-length tau
(4R0N) after cycloheximide treatment halted protein synthesis
(65). Similarly, overexpressing the FTDP-17 mutant P301L tau in
SH-SY5Y cells and then treating with lactacystin led to significantly
increased tau levels (70). Lactacystin also caused accumulation of
endogenous tau in the HT22 murine neuronal cell line (71). In
immortalized mouse cortical neuronal cells inducibly expressing
full-length wild-type tau, EPX slowed the degradation of full-
length tau (72). In M1C neuroblastoma cells that inducibly express
wild-type full-length tau (4R0N),EPX,and MG-132 induced accu-
mulation of full-length tau but there was a concomitant loss of
C-terminus immunoreactivity (64). This was attributed to cas-
pase cleavage, as activated caspase-3 was detected, and a caspase
inhibitor preserved C-terminal immunoreactivity (64). Addition-
ally, incubation of rat brain extract (containing endogenous tau
and proteasomal enzymes) with the proteasome activators Mg2+
and ATP resulted in lower total tau levels with an increase in
smaller forms, compared to extract not supplemented with Mg2+
and ATP (73). The loss of tau was blocked by lactacystin giv-
ing further evidence that the proteasome was degrading tau (73).
The story is more complex, however, as proteasomal inhibition
under physiological conditions does not consistently lead to tau
accumulation. For example, treatment of primary neurons with
an Hsp90 inhibitor to interrupt the proper chaperoning of tau
leads to decreased levels of tau. Adding MG-132 to block the pro-
teasome prevented the Hsp90 inhibitor-induced reduction in total
tau. MG-132 alone had no effect on tau levels (67). This might sug-
gest that under normal circumstances, if proteasomal impairment
occurs, tau levels are maintained by autophagic degradation. But
when the system is pushed to promote proteasomal degradation
over autophagy – such as by inhibiting Hsp90 – then the homeo-
static maintenance of tau levels is disrupted and tau degradation
does not occur when the proteasome is inhibited.
AUTOPHAGY
Autophagy is the process of “self-eating.” Under starvation con-
ditions, bulk autophagy can be induced to catabolize cellular
substrates to generate energy. However it is now evident that
autophagy is an ongoing clearance mechanism for larger, longer-
lived proteins and aggregates, as well as organelles such as mito-
chondria and peroxisomes (74) and pathogenic bacteria (75–77).
There are three forms of autophagy: microautophagy, macroau-
tophagy, and chaperone-mediated autophagy. The most common
and well understood is macroautophagy, hereafter referred to sim-
ply as autophagy. For a more complete review of autophagy, see
(78). Briefly, a double membrane autophagophore is initiated and
subsequently expanded to engulf a region of cytoplasm containing
the substrate/substrates to be degraded, such as tau (see Figure 2).
Once fully formed into an enclosed vesicle called an autophago-
some, it is trafficked to a lysosome where it undergoes fusion
to become an autophagic vacuole (AV). The lysosomal enzymes
degrade the inner membrane of the autophagosome as well as the
delivered contents. The enzymes responsible for degrading pro-
tein substrates of autophagy are the cathepsins. Once the contents
are fully degraded the lysosome is regenerated via acidification
through vacuolar ATPases. There are 15 core autophagy related
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genes (Atgs) that are involved in the process of autophagy. Many
of these have E1, E2, or E3 ligase activity to catalyze the reactions
necessary for the initiation and expansion of the autophago-
somal membrane. Critical early steps in the formation of the
autophagopore require a complex of Atg proteins that conjugate
phosphatidylethanolamine onto Atg8 family members (includ-
ing LC3), a process that is critical for allowing expansion of the
autophagosomal membrane. Conjugated LC3, called LC3-II, is the
canonical marker of autophagosomes. Atg7 is a critical E1 ligase
for several of the reactions necessary for autophagy (74).
EVIDENCE THAT AUTOPHAGY IS IMPAIRED IN AD
There is significant support for the possibility of defective
autophagy in AD. Electron microscopic analysis of brain tissue
from confirmed AD cases revealed that AVs accumulated in dys-
trophic neurites and correlated with the presence of filamentous
tau (79). However, this correlation was not quantified (79). Similar
results were observed in mouse models of AD. For example, in a
presenilin 1 (PS1)/Amyloid Precursor Protein (APP) double trans-
genic mouse, AVs were prevalent in dystrophic neurites at as early
as 4.5 months without a similar accumulation of other structures
such as lysosomes (80, 81). In these transgenic mice LC3-positive
bodies were particularly apparent in neurites surrounding amy-
loid plaques, and immunoblotting of hippocampi from 6 month
old transgenic PS1/APP mice revealed increased levels of LC3-
II compared to wild-type mice (81). It is well established that
mutations in PS1 result in familial AD, and until recently it was
thought that this was only due to alterations in APP processing.
However PS1 has a number of non-secretase functions, including
acting as the chaperone for the vacuolar-ATPase used to acidify
the lysosomal lumen (82, 83). Mutations in PS1 were shown to
impair the acidification of lysosomes, which is necessary for acti-
vating the proteolytic enzymes in this compartment. Improper
acidification and impaired proteolysis of substrates would com-
promise the autophagy system and result in the accumulation
of AVs as described above. However, another mouse model, the
TgCRND8 mouse, which expresses mutant APP only, also has
increased staining for LC3-II, as well as an increase in cathepsin
D-positive lysosomes (84). This demonstrates that in the absence
of mutant PS1, AD-associated impairment in autophagy occurs
and thus is due to other factors. Treatment of ex vivo hippocampal
slice cultures with lysosomal disruptors causes the formation of
enlarged, dystrophic neurites filled with AVs and lysosomes, simi-
lar to what is seen in mouse AD models and human AD tissue (85,
86). It has also been suggested that specific cathepsins may become
extralysosomal in certain diseases, including AD (87, 88). Together
these observations implicate a possible failure of autophagy as part
of AD pathogenesis.
EVIDENCE TAU CAN BE DEGRADED BY AUTOPHAGY
As indicated above, a functioning lysosomal compartment is
critical for the completion of autophagy. Given the possibility
of a defect at this level of autophagy, numerous studies have
directly assessed the effects of impairing lysosomal function on
tau turnover, including specifically targeting the cathepsins. In an
early study the direct cleavage of tau by cathepsin D was inves-
tigated in an in vitro assay using tau partially purified from rat
brain in combination with cathepsin D from human liver. Incu-
bation of tau with cathepsin D at pH 4.0 resulted in a decrease in
full-length tau and a concomitant increase in cleaved fragments
of varying sizes (89). Similarly, adding exogenous cathepsin D to
homogenates of rat cortex at a neutral pH also generated tau frag-
ments. Intriguingly, if a cysteine protease inhibitor was added to
the assay, tau cleavage stopped at the 29-kDa fragment, suggesting
that cathepsin D (an aspartyl protease) could cleave tau to a 29-kDa
fragment after which other proteases may act to further degrade
the protein. This also suggests if cathepsin D was able to escape
from the lysosome, for example in the context of an AD-related
stressor, it could still function in the neutral environment of the
cytosol. However, the activity of cathepsin D at the more neutral
pH may be more impeded than appears, as a previous study found
cathepsin D’s proteolytic activity was significantly reduced above
pH 6.0 (90). Treating hippocampal slices with chloroquine (CQ),
which raises the pH of lysosomes to impair enzymatic function,
was associated with increased levels of full-length tau (89, 91).
This was in conjunction with an accumulation of intracellular
PHF1 immunopositive tau (91). In M1C neuroblastoma cells that
inducibly express full-length wild-type tau (4R0N), treatment with
CQ also significantly slowed down tau degradation, and caused
its accumulation (92). Treatment of hippocampal slices with the
cathepsin modulator ZPAD (which stimulates cathepsin D very
strongly) appears to increase the proteolysis of full-length tau
resulting in the production of smaller fragments, including a phos-
phorylated 29 kDa fragment (86, 89). This partial degradation of
tau was inhibited by inclusion of a selective cathepsin D inhibitor
(86). Cathepsin D seems particularly important for degrading tau,
as its expression was neuroprotective in a Drosophila tauopathy
model. Levels of cathepsin D are elevated in flies expressing mutant
human tau. If cathepsin D is genetically ablated, these tau flies
exhibit enhanced neurotoxicity and a shorter lifespan (93).
Modulating autophagy through other approaches also indi-
cates that tau can be degraded through this pathway. Overex-
pressing only the repeat domain of tau containing an FTDP-17
mutation in neuroblastoma cells leads to tau aggregation as well
as the appearance of smaller proteolytic fragments. Using the
autophagy inhibitor 3-methyladenine (3-MA) to block the for-
mation of autophagosomes led to an increase in both soluble
and insoluble tau (94). Directly activating autophagy through a
variety of mechanisms leads consistently to enhanced tau clear-
ance – either pathological forms or total tau. In a hippocampal
slice preparation methylene blue was used to induce autophagy,
which resulted in a decrease in phosphorylated tau and insoluble
tau, specifically (95). In a cell line expressing the repeat domain
of tau containing the FTDP-17∆K280 mutant, treatment with the
disaccharide trehalose, an mTor-independent autophagy activator,
significantly reduced aggregated tau as measured by Thioflavin-S
staining, as well as total tau levels both soluble and insoluble as
detected by western blotting (96). Stimulating autophagy either
through serum withdrawal or rapamycin treatment in SH-SY5Y
cells overexpressing P301L tau that had been induced to aggregate
led to substantial reduction in aggregates that was prevented by
3-MA (70). In a mouse model expressing the FTDP-17 mutant
P301S, promoting autophagy with trehalose treatment beginning
at weaning significantly reduced insoluble tau, as well as tau
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phosphorylated at T212/S214 (AT100) (97). However, no other
phosphorylation sites were assessed. This effect was correlated
with improved neuronal survival in cortical layers I–III (97). Stim-
ulating autophagy via genetic manipulation of the mTor pathway
decreased total and phosphorylated tau in the same mouse model
(98). Conversely, inhibiting autophagy (also via mTor) lead to
increased total and AT8-positive phosphorylated tau (98). Mice in
which the critical autophagy gene Atg7 is knocked out in forebrain
neurons develop age-dependent neurodegeneration with accu-
mulation of phosphorylated tau within intracellular inclusions
(99). These inclusions specifically contained tau phosphorylated
at AT8, AT100, and TG3 epitopes, but not PHF1. Significantly,
if tau was also knocked out in these autophagy-deficient mice,
neurodegeneration was reduced (99).
Interestingly, other evidence for the role of autophagy in clear-
ing tau was the result of attempting to elucidate the role of the
proteasome in tau degradation. Treating rat primary neurons
with the proteasomal inhibitor MG-132 actually led to a reduc-
tion in total tau. This effect was likely due to a compensatory
upregulation of autophagy, as evidenced by increased LC3-II pro-
tein and an increased number of autophagosomes in treated cells
(96). This will be discussed in more detail below, as it has impor-
tant ramifications for the intersection of these two degradative
pathways.
INTERPLAY BETWEEN AUTOPHAGY AND THE PROTEASOME
There is compelling evidence for significant and extensive inter-
play between the autophagy and proteasomal systems. This has
intriguing implications for disease processes and specifically tau
degradation in AD. First, while each system preferentially degrades
specific substrates, there are many substrates that can be degraded
by both systems, tau being a prime example (25). For instance,
a particular substrate may be degraded by the proteasome under
normal conditions, but if that system is impaired and/or there is
an excess of that substrate it may be degraded in a compensatory
manner by autophagy. Another possibility is that particular forms
of a substrate may be shuttled to one pathway or another. In the
case of tau, as a monomer it is natively unfolded and hence a likely
proteasomal substrate, as discussed above. However, any of the
numerous modifications tau undergoes during AD pathogenesis
may render it less able to do so, for example, by inducing con-
formational changes to a more ordered structure as suggested by
several conformation-specific antibodies that label tau in AD brain
(Alz-50, MC-1, etc.). Additionally, oligomerized or aggregated tau
may not be a preferred proteasomal target. It has been suggested
that this change in state is part of the signal for tau to be degraded
by autophagy. This is supported by evidence that full-length tau,
which has a lower propensity for aggregating, is cleared by the pro-
teasome while caspase-cleaved tau, which is more aggregate prone,
goes through autophagy (72). Also, aggregated tau can be cleared
by inducing autophagy (70, 96).
Ubiquitin is implicated in targeting substrates to both path-
ways. Historically, poly-ubiquitin chains generated through lysine
48 (K48) linkages were viewed as the prototypical proteasomal
targeting sequence, while K63 chains appeared more specific for
autophagy. However, the experimental evidence indicates a more
complex picture. For example, if HEK cells are transfected with
tau and ubiquitin, tau is readily ubiquitylated and degraded by
the proteasome (66). However, if a ubiquitin construct contain-
ing a site mutation at K63 is transfected in, no ubiquitylation of
tau occurs. Other mutated forms of ubiquitin, including ubiquitin
unable to form linkages at K48, still resulted in tau ubiquitylation.
This indicates that in this experimental overexpression paradigm,
K63 linkages are the primary ubiquitin linkage for tau, and they
target tau to the proteasome rather than to autophagy (66). How-
ever, another study, also using HEK cells and ubiquitin K48 and
K63 mutants, demonstrated that in the presence of the E3 ligase
CHIP, tau could be ubiquitylated by both K48 and K63 linkages
(100). The likelihood that in vivo tau can be ubiquitylated in mul-
tiple ways is supported by studies showing tau isolated from NFTs
in human brain has several forms of ubiquitin linkages as well
as mono-ubiquitylation (101, 102). These data suggest that the
physical structure of the ubiquitin chain is unlikely to be a suffi-
cient signal for selectively targeting tau to either the proteasome
or autophagy. An alternate mechanism for specifically targeting
substrates is the involvement of chaperone proteins. The chaper-
ones involved in proteasomal targeting are not well characterized,
although it is known that ubiquitin-tagged substrates are trafficked
to the organelle. Currently identified chaperones include p62 and
Hsp70 (66, 100). Slightly more is known about autophagy adap-
tors, and there is significant overlap, as both p62 and Hsp70 are
adaptors for this pathway as well (103, 104). This further compli-
cates the understanding of how a substrate is selectively targeted
to one path or the other. For example, a ubiquitylated substrate
can be bound by p62 and either delivered to the proteasome (66)
or engulfed by an autophagosome via p62 binding to LC3 (105).
These findings suggest the involvement of a currently unidentified
chaperones and/or targeting signals, or undetermined additional
factors.
Other characteristics of the substrate are likely to also play a
role in successfully targeting the protein either to the proteasome
or to autophagy. In the case of tau, two modifications seem to
be critical for this process: phosphorylation and truncation. For
example, in the study where rat brain extract was incubated with
Mg2+ and ATP, there was an overall decrease in tau due to protea-
somal activity; however tau phosphorylated at the PHF1 and Tau-1
epitopes seemed to be preferentially degraded as they were non-
detectable within 3 h (73). The preferential degradation of specific
phospho-forms of tau by a particular pathway has been reported in
other studies as well. In CHO cells overexpressing P301L mutant
tau, treatment with the Hsp90 inhibitor geldanamycin led to a
more pronounced proteasome-mediated reduction in tau phos-
phorylated at proline-directed S/T sites compared to total tau (67).
However, the levels of tau phosphorylated at KXGS sites within the
repeat domain were not reduced by geldanamycin treatment. In
agreement with those findings, inhibiting autophagy in primary
rat cortical neurons with 3-MA resulted in the selective accumu-
lation of tau phosphorylated at the KXGS motif S262 (recognized
by the 12E8 antibody) (106). Additionally, in a hippocampal slice
preparation, induction of autophagy by treatment with methyl-
ene blue led to a decrease in phosphorylated tau and insoluble
tau without an effect on total tau (95). Activating autophagy with
trehalose in rat cortical neurons demonstrated certain phospho-
epitopes (AT8, PHF1, and 12E8) were reduced more significantly
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than total tau – up to 80% compared to the 20% reduction in total
tau (96). Finally, caspase-3 cleaved tau has a shorter half-life than
full-length tau and is preferentially degraded by autophagy (72).
Additional modified forms of tau have yet to be fully examined for
their preferred route of degradation.
As specific substrates are targeted to one degradative path-
way or the other, the function of each system can also directly
impact the functioning of the other. It is well documented that
blocking the proteasome with small molecule inhibitors causes
an increase in autophagic flux (107). This can be seen both as
increased autophagosome formation and maturation as well as
enhanced degradation of autophagy substrates (96). However the
converse is not true; autophagy impairment does not elevate pro-
teasomal function and, in fact, rather strikingly inhibits it. There
are several possible mechanisms for this inhibition. The accumu-
lation of large aggregated substrates might impair the proteasome,
as seen for PHF tau (69). Also, reduced recycling of p62 by impair-
ing autophagy (causing its accumulation) will impair proteasomal
processing, potentially by p62 competing with other chaperones
for proteasomal targets and impeding their delivery (107). The
degradation of tau is thus a complex process mediated by multi-
ple factors. While much is known about how tau can be cleared,
additional studies are needed to clarify what actually happens in
both the normal brain and in the context of AD. This information
will yield critical insights into potential therapeutics.
ROLE OF OLIGOMERS IN AFFECTING TAU DEGRADATION
DECISIONS
Given the data indicating tau can be processed by both autophagy
and the proteasome, and furthermore that the signaling mecha-
nisms directing substrates to either path are shared, it is unclear
how decisions regarding which way tau is degraded are made. One
possibility could be tau’s physical state of oligomerization. Solu-
ble, monomeric tau is an ideal proteasomal substrate. Indeed, it
has been clearly demonstrated that tau can be degraded by the
proteasome (65–67, 73). It thus can be suggested that under phys-
iologic circumstances much of tau is degraded in this manner,
with select modified forms being cleared by autophagy. However,
within the context of the AD milieu, additional tau modifica-
tions and degradative impairments may cause the balance to shift
away from proteasomal degradation toward autophagy. For exam-
ple, as discussed above, certain modified forms of tau, such as
caspase-cleaved tau, have a stronger tendency to aggregate. As tau
begins to assemble into oligomers, it may become increasingly
undesirable as a proteasomal substrate. These low-order, soluble
oligomers may be preferentially degraded by autophagy. However,
FIGURE 3 | Alzheimer disease-related disruption of tau degradation.
Impairment of protein degradation is a known component of both familial
and sporadic AD. Familial AD-related mutations of PS1 are linked to
impairment of lysosomal acidification and/or fusion to the autophagosome,
while sporadic factors leading to similar impairments have not yet been
elucidated. Impairment of the lysosome/autophagosome leads to
accumulation of dysfunctional autophagic vacuoles (AVs), cytosolic p62,
and aggregates of tau. Dysfunction of autophagy further inhibits the
proteasome, possibly via accumulation of p62, which can be a chaperone
for both systems. P62 is usually recycled via autophagy and accumulates
in the cytosol when autophagy is impaired. Hypothetically, this allows p62
to compete with other proteasome chaperones thus inhibiting
proteasomal degradation. Further, accumulation of aggregated proteins
has also been shown to inhibit the proteasome. Taken together, this could
lead to accumulation of soluble tau, and thus more proteolytic processing
and further aggregate. Hence, a vicious cycle of degradative pathway
impairment and tau accumulation/aggregation may contribute to the
neurodegenerative processes in AD.
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as previously discussed, autophagy is likely impaired in AD. The
tendency for certain phospho-epitopes to show preferential clear-
ance by certain pathways may also relate to their propensity for
aggregation. As tau oligomers increase in size, density, and mod-
ifications during the development of filaments and tangles, not
only will they be unable to undergo proteasomal degradation,
they may directly impair proteasomal function (69). This pro-
teasomal impairment could have multiple effects. For example,
autophagy may initially be activated as a compensatory response.
Caspase-3 and possibly other proteases may also be activated as
well. However, this may result in an accumulation of potentially
toxic cleaved forms of tau. Additionally, given the significant evi-
dence that autophagy is impaired in AD, possibly at the level of the
lysosomes, proteasomally mediated activation may serve to further
obstruct the autophagy system (see Figure 3).
CONCLUSION
It is clear that tau plays a significant role in AD pathology, although
the mechanisms involved have not been clearly delineated. Tau
is a normal neuronal protein that modulates microtubule-based
functions, and becomes increasingly hyperphosphorylated, trun-
cated, and otherwise modified in AD. These modifications not
only impair tau’s normal function, but also appear to promote its
oligomerization. These oligomers eventually accumulate to form
the NFTs which are pathognomonic for AD. While the NFTs may
be harmful to the cell in some ways, it is now believed that the prin-
cipal toxicity results from pre-aggregated, soluble tau oligomers.
Thus, understanding how these tau species can be cleared may
allow for the development of effective therapeutic approaches. It
is clear from the data that certain species of tau are preferentially
degraded by the proteasome and others by autophagy. There is evi-
dence that both of these degradative systems are likely impaired
at some level in AD. Additionally, there is a complex interplay
between the proteolytic and degradative pathways that suggests
a cycle of pathology may develop in AD whereby alterations in
tau processing, including by cytosolic proteases, pushes more
tau toward the autophagy system. Decreased autophagic func-
tion would result in accumulation of these autophagy-cleared tau
species. The combination of impaired autophagy and accumulat-
ing substrates has the potential to lead to proteasomal inhibition,
in addition to other factors (such as Aβ) that may impair the
proteasome in AD (108). This then further promotes cytosolic
accumulation of tau leading to its aggregation. Additionally, mod-
ifications including caspase-3 cleavage and hyperphosphorylation
promote aggregation even of full-length tau, reducing the pool of
functional tau.
Understanding how tau is cleared may enable us to identify
potential mechanisms for enhancing clearance of pathological
forms of tau. Ameliorating the deficit in autophagy is a likely tar-
get for this process, and initial results of stimulating autophagy
show promise for clearing tau. Indeed, several studies aimed at
stimulating autophagy have demonstrated efficacy in reducing
phosphorylated and aggregated tau in both in vitro and in vivo
models (95–98). These studies are an important initial step toward
elucidating the exact role of tau degradation in modulating neu-
rodegeneration in AD. Further studies that better gauge the con-
tribution of each degradative pathway will be necessary. Due to the
complexity of the cellular environment, in vitro studies that can
tightly control for variables including tau modifications and pro-
teolytic pathway function will likely be instrumental. Ultimately,
a more complete understanding of the differential contribution
of various proteolytic and degradative pathways will provide criti-
cal opportunities for therapeutically addressing the tau pathology
associated with neurodegeneration in AD.
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